Staff

Rolland A. Reinbold

Primo Ricercatore
E-Mail

rolland.reinbold@cnr.it

PHONE

+390226422644

LOCATION

Segrate

ROOM (floor/number)

6/23

After a Bachelor degree in Physics, a Master in Biology and a PhD in Molecular and Cellular Biology, I obtained a Unit Leader permanent postion in Stem Cell Reprograming and Biomedical Research in Hans Schoeler’s Lab (1999-2009) at the EMBL-Heidelberg (DE), University of Pennsylvania (USA) and Max Planck Institute (GE). My research at the EMBL, UPenn and Max Planck allowed fundamental discoveries defining pluripotency of embryonic stem cells (ESC) and induced pluripotent stem cells (iPSCs). My studies also led to the first demonstration that epgenomic cell reprograming of ESC can be used to generate germ cells for clinical applications (recognized as one of the top research breakthroughs for 2003 by the journal Science) laying the foundation for future regenerative medicine applications. In 2009 after a voluntary termination of the Max Planck permanent position due to family reasons, I obtained a fellowship from the Italy-Harvard program to work at the ITB-CNR, to develop iPSCs for clinical and research disease models and therapy. In 2010 a Cariplo Foundation grant for young foreign researcher recruitment (Somatic cell reprogramming: a potential source for tissue repair and regeneration) allowed me to transfer at the ITB my expertise, tools and technologies in iPSCs generation, cell reprogramming and 3D organoid formation and to initiate my activity as an independent PI and group leader. In 2019 I obtained a permanent Researcher postion at the ITB. From 2019 two patents were submitted and granted: the EU Patent EP18707150.1: New method and agent for cellular reprogramming (2019), the EU patent BE1595R/RVP/US patent US11566070B2: New regulator of angiogenesis (2023). My current research interests include metabolism, glycomics, subcecullar organelles, autoimmune diseases, angiogenesis, neurodegeneration, cancer and aging. My collaborations span USA, Russia, Europe and South America. Recent funding includes Nutrage (2022-25) and EU Grant Horizon (2024-26). I currently am in the board of the Renato Dulbecco Foundation Association AFRD (Established in 1994).

Metabolomic analysis of mitochondria, endoplasmic reticulum, vesicle trafficking.

Identification of post-translational and gene-read mechanisms in disease and therapeutic applications.

Regulation of gene expression by transient or constitutive modulation of genes to provide insights into gene function and therapeutic potential in disease models

Development, application and optimization of automated pipelines for the analysis of genomics, epigenomics and transcriptomics data for large-scale studies.

Study of molecular and cellular mechanisms in tumorigenesis with a focus on dissecting cellular heterogeneity and interactions within the tumor microenvironment

Development of 3D patient-derived organoids recapitulating in vitro disease models to study the interactions between host and components of surrounding microenvironment